Study on Enzalutamide with Hormone and Radiation Therapy for High-Risk Localized Prostate Cancer

Inclusion Criteria

• Diagnosed with prostate cancer that is considered high risk for returning, based on specific medical criteria like a high Gleason score or certain PSA levels.
• Aged 18 years or older.
• Have good bone marrow, liver, and kidney function as shown by specific blood tests.
• Be in good overall health with a performance status score of 0 or 1, meaning fully active or restricted in physically strenuous activity but ambulatory.
• Able to start the study treatment within 7 days of being assigned to a treatment group.
• Willing to follow all study requirements, including attending appointments and completing questionnaires.
• Have signed a consent form agreeing to participate in the study.

Exclusion Criteria

• Have prostate cancer with certain rare cell types.
• Have cancer that has spread to lymph nodes outside the pelvis.
• Have any condition that prevents safe use of radiation therapy.
• Have a history of seizures or conditions that increase seizure risk.
• Have had a recent heart attack or other serious heart problems.
• Have evidence of cancer spread to other parts of the body.
• Have a PSA level over 100 ng/mL.
• Have had another cancer within the last 5 years, except for certain skin or bladder cancers.
• Have any serious illness or infection that could affect study participation.
• Have psychological or social issues that could interfere with the study.
• Are sexually active and not using effective birth control.
• Have used certain hormone therapies recently, except for specific short-term use.
• Have had certain surgeries or treatments that affect the prostate.
• Are participating in another clinical trial.
• Have had major surgery recently.
• Have digestive issues that affect the absorption of the study drug.